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tIn the reward circuitry of the brain, alpha-7-nicotinic acetylcholine receptors (α 7nAChRs)
modulate effects of delta-9-tetrahydrocannabinol (THC), marijuana’s main psychoactive
ingredient. Kynurenic acid (KYNA) is an endogenous negative allosteric modulator of
α 7nAChRs. Here we report that the kynurenine 3-monooxygenase (KMO) inhibitor Ro 61-8048
increases brain KYNA levels and attenuates cannabinoid-induced increases in extracellular
dopamine in reward-related brain areas. In the self-administration model of drug abuse, Ro
61-8048 reduced the rewarding effects of THC and the synthetic cannabinoid WIN 55,212-2 in
squirrel monkeys and rats, respectively, and it also prevented relapse to drug-seeking induced by
re-exposure to cannabinoids or cannabinoid-associated cues. The effects of enhancing endogenous
KYNA levels with Ro 61-8048 were prevented by positive allosteric modulators of α 7nAChRs.
Despite a clear need, there are currently no medications approved for treatment of marijuana
dependence. Modulation of KYNA provides a novel pharmacological strategy for achieving
abstinence from marijuana and preventing relapse.
The number of people seeking treatment for marijuana abuse in the U.S. (1,243,000) is
higher than the number seeking treatment for cocaine or heroin use (787,000 or 507,000,
respectively) (NSDUH)1. Like other drugs of abuse, marijuana’s rewarding effects involve
neurochemical changes in brain reward systems2,3. Specifically, THC, the main
psychoactive ingredient in marijuana, activates mesolimbic dopamine circuitry by enhancing
the firing of dopamine neurons in the ventral tegmental area (VTA)4,5, resulting in increased
release of dopamine from nerve terminals in the shell of the nucleus accumbens (NAc)6,7.
Developing medications that modulate these effects of THC on reward signaling might
provide a therapeutic approach for the treatment of marijuana dependence. Alpha-7-nicotinic
acetylcholine receptors (α 7nAChRs) are present in both the VTA and NAc shell, where they
are localized on glutamatergic nerve terminals8. Their activation elicits the release of
glutamate, which in turn acts at ionotropic glutamate receptors on dopaminergic terminals to
stimulate dopamine release9,10. We previously found that reward-related behavioral and
neurochemical effects of THC or the synthetic cannabinoid-receptor agonist WIN 55,212-2
could be blocked by methyllycaconitine (MLA), a selective antagonist at α 7nAChRs,
pointing to modulation of α 7nAChR activity as a pharmacological approach for treating
marijuana dependence11,12. Unfortunately, systemic use of cholinergic antagonists acting
directly at α 7nAChRs is associated with central and peripheral side effects that limit their
therapeutic utility13,14. Medications that enhance the formation of endogenous negative
allosteric modulators of α 7nAChRs might be better tolerated than directly-acting cholinergic
antagonists15-17. Allosteric modulators change receptor conformations in the presence of
orthosteric ligands, and often have no effect on their own, acting only when physiological
receptors are activated15-17.
Kynurenic acid (KYNA) is an endogenous neuroinhibitory metabolite18, which is produced
by the irreversible transamination of kynurenine, the first major catabolic product of
tryptophan. Formed in astrocytes19, KYNA is present in the mammalian brain in nanomolar
concentrations20. Long known as a competitive antagonist of the glycine co-agonist site of
the NMDA receptor21, KYNA is also a negative allosteric modulator of α 7nAChRs at
endogenous concentrations, and somatodendritic and preterminal/presynaptic α 7nAChRs
are equally sensitive to KYNA22-24. Notably, fluctuations in brain KYNA levels have
neuromodulatory consequences. Thus, reductions in brain KYNA cause an increase in
extracellular levels of acetylcholine, dopamine and glutamate25-27, whereas KYNA
elevations reduce α 7nAChR function and result in α 7nAChR-dependent, but relatively
modest, decreases in extracellular levels of glutamate and dopamine in the striatum,
prefrontal cortex, and caudate nucleus26,28,29. It has therefore been proposed that astrocyte-
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tderived KYNA, through this indirect action, may serve as an endogenous modulator of both
physiological and pathological glutamatergic and dopaminergic signaling30.
We hypothesized that pharmacological enhancement of brain KYNA levels could
selectively counteract the behavioral and neurochemical effects of THC responsible for
marijuana abuse and dependence, notably the ability to support the development of
persistent drug-taking behavior31, to precipitate relapse to drug-seeking behavior in
abstinent subjects32, and to increase dopamine release in the nucleus accumbens shell6,7.
Production of KYNA in the brain and elsewhere can be increased by inhibiting kynurenine
3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan
degradation33,34. In both rodents and monkeys, peripheral KMO inhibition results in
elevated blood levels of KYNA’s precursor kynurenine35,36, which readily penetrates the
blood-brain barrier and accumulates in astrocytes where it undergoes transamination to
KYNA19,37. Newly formed KYNA is promptly released into the extracellular
compartment38. Notably, no reuptake processes exist for KYNA, and extracellular KYNA is
not degraded enzymatically39 but is slowly eliminated from the brain by a non-specific acid
transporter20,40.
In this study, we used 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide
(Ro 61-8048), a potent, selective, peripherally-acting KMO inhibitor41, to indirectly increase
brain KYNA levels. We combined neurochemical and behavioral approaches to evaluate
effects of Ro 61-8048 on: (1) KYNA levels in the VTA and NAc shell in rats; (2) elevations
of extracellular dopamine in the NAc shell and VTA induced by THC or the synthetic
cannabinoid WIN 55,212-2 in rats; (3) THC self-administration in squirrel monkeys and
WIN 55,212-2 self-administration in rats; (4) drug-induced and cue-induced relapse to
cannabinoid-seeking behavior in abstinent animals; (5) cocaine self-administration and food-
rewarded behavior in monkeys to assess specificity of the effect; and (6) working memory
and THC discrimination in rats and squirrel monkeys, to assess potential side effects. To
further elucidate the mechanism of the observed effects, we determined whether infusing
KYNA locally in the NAc shell prevents THC-induced elevations of dopamine in the NAc
shell of rats.
Results
Neurochemical effects of KMO inhibition in rats
We tested whether systemic administration of the KMO inhibitor Ro 61-8048 would
increase levels of KYNA in two brain regions implicated in rewarding effects of
cannabinoids: the NAc shell and VTA. In-vivo microdialysis experiments in freely-moving
rats showed that systemic administration of 30 and 100 mg per kg (i.p.) of Ro 61-8048
increased extracellular KYNA levels in the NAc shell by 150% and ~225%, respectively
(Fig. 1a; 30 mg per kg: F11,55 = 28.59; P < 0.001; 100 mg per kg: F11,55 = 15.03; P < 0.001).
In the VTA, the 30 and 100 mg per kg doses of Ro 61-8048 elevated KYNA levels to 50%
and 200%, respectively (Fig. 1b; 30 mg per kg: F11,55 = 5.85; P < 0.001; 100 mg per kg:
F11,55 = 24.18; P < 0.001). Peak KYNA levels in both NAc and VTA were observed 80 min
after injection of 100 mg per kg Ro 61-8048 and 140 min or later after injection of 30 mg
per kg Ro 61-8048.
We then determined whether systemic administration of Ro 61-8048 would block THC-
induced elevations of dopamine in the NAc shell and VTA in rats. In the NAc shell, THC (3
mg per kg, i.p.) significantly increased extracellular dopamine (Fig. 2a,b; Treatment × time
interaction, F30,218 = 1.99; P < 0.003; AUC: F3,22 = 6.06; P = 0.0036), but pretreatment with
30 or 100 mg per kg of Ro 61-8048 dose-dependently blocked this effect of THC (Fig. 2a,b).
We saw similar effects in the VTA, where THC (3 mg per kg) also increased extracellular
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tdopamine significantly (Fig. 2c,d; Treatment × time interaction, F30,188 = 4.25; P < 0.0001;
AUC: F3,19 = 22.01; P < 0.001), and pretreatment with either 30 or 100 mg per kg of Ro
61-8048 significantly reduced this effect of THC (Fig. 2c,d). When given alone, Ro 61-8048
(100 mg per kg) did not significantly affect dopamine levels in either the NAc (Fig. 2a) or
the VTA (Fig. 2c,d).
This finding that systemic administration of Ro 61-8048 blocks the effects of THC on
dopamine in reward-related brain areas, coupled with the finding that Ro 61-8048 increases
KYNA in these areas, led us to determine whether the effects of THC on dopamine could be
blocked by infusing KYNA directly into the NAc shell. We observed that THC (3 mg per
kg, i.p.) significantly increased extracellular dopamine in the NAc shell of freely-moving
rats when the local tissue was continually infused with vehicle, but not when the tissue was
continually infused with KYNA (500 nM) (Fig. 2e,f: Treatment × time interaction, F14, 91 =
3.61; P < 0.0001; AUC: F2,13 = 13.64; P = 0.0006). In the absence of THC, local infusion of
KYNA (500 nM) into the NAc shell had no effect on dopamine levels (Fig. 2e,f).
To verify that the ability of Ro 61-8048 to block THC-induced dopamine elevations in the
NAc shell were due its actions at α 7nAChRs, we reversed the effects of Ro 61-8048 with
galantamine and PNU120596, both agonists at the allosteric potentiating site of α 7nAChRs
where KYNA acts23,42. In these two experiments (one with galantamine and one with
PNU120596), we again found that systemic Ro 61-8048 (100 mg per kg, i.p.) significantly
decreased the ability of THC (3 mg per kg, i.p.) to raise dopamine levels in the NAc shell
(replicating the effect seen in Figs. 2a,b), reducing the area under the curve by about 60 to
70% (Fig. 3a; F5,27 = 8.34, P < 0.001; Fig. 3b; F4,17 = 9.87, P < 0.0003). Furthermore, we
observed that pretreatment with galantamine (Fig. 3a; 3 mg per kg, i.p.) or PNU120596 (Fig.
3b; 1 mg per kg, i.p.) reversed this effect of Ro 61-8048. Neither galantamine nor
PNU120596 altered dopamine levels when given alone, nor did they alter the effects of THC
(Fig. 3a,b). Thus, we confirmed that α 7nAChRs are involved in the ability of Ro 61-8048 to
block THC-induced dopamine elevations in rats.
To determine whether treatment with Ro 61-8048 alters the effects of cannabinoid CB1
agonists other than THC, we studied dopamine elevations induced by the synthetic agonist
WIN 55,212-2. Like THC, WIN 55,212-2 (0.3 mg per kg, i.v.) significantly increased
extracellular dopamine levels in the NAc shell (Fig. 4a; Treatment × time interaction, F28,98
= 3.28, P < 0.0001). Although Ro 61-8048 (30 or 100 mg per kg) alone did not affect
dopamine levels (Fig. 4b), pretreatment with 30 or 100 mg per kg of Ro 61-8048
significantly reduced the ability of WIN 55,212-2 to increase dopamine levels in the NAc
shell (Fig 4a,c; AUC: F4,14 = 3.73; P = 0.0288).
Behavioral effects of KMO inhibition in rats
Having determined that the KMO inhibitor Ro 61-8048 can block the effects of cannabinoid
CB1 agonists in reward-related brain areas, we tested the effects of this treatment in
behavioral models of cannabinoid abuse. We first turned to a rodent model of cannabinoid
reinforcement in which rats intravenously self-administer WIN 55,212-2 (12.5 μ g per kg per
injection). This synthetic cannabinoid had a clear reinforcing effect, causing rats to respond
significantly more on the lever that delivered the drug than on an inactive control lever (Fig.
4d,e; F1,4 = 23.95, P = 0.008). Treatment with 30 or 100 mg per kg Ro 61-8048 40 min
before each session significantly decreased self-administration of WIN 55,212-2 (Fig. 4d; 30
mg per kg: F3,12 = 19.5, P < 0.001; Fig. 4e; 100 mg per kg: F3,12 = 6.92, P = 0.006). The 100
mg per kg dose of Ro 61-8048 decreased self-administration responding over all three days
of testing, but it also significantly affected responding on the inactive lever (Fig. 4e; F3,12 =
18.35, P < 0.001). This effect on inactive-lever responding was not seen with 30 mg per kg
Ro 61-8048 (Fig. 4d; F3,12 = 1.76, P = 0.21), yet this lower dose was effective in blocking
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tthe self-administration of WIN 55,212-2. Self-administration quickly recovered to baseline
levels when Ro 61-8048 treatment was discontinued.
Since relapse to drug use after long periods of abstinence represents one of the greatest
challenges for the treatment of addiction, we also investigated whether Ro 61-8048 would
block reinstatement of drug seeking by abstinent rats in an animal model of relapse. When
WIN 55,212-2 delivery was discontinued, rats’ drug-seeking behavior decreased to low
levels (Fig. 4f). A non-contingent priming injection of WIN 55,212-2 (0.3 mg per kg., i.p.,
10 min before the session) reinstated drug-seeking behavior, but this relapse-like effect was
completely blocked by pretreatment with 100 mg per kg Ro 61-8048 (Fig. 4f; F5,20 =
231.13, P < 0.001). None of these treatments significantly affected responding on the
inactive lever (Fig. 4f). Thus, Ro 61-8048 prevented the relapse-like effect induced by re-
exposure to cannabinoids in rats.
KMO inhibition and THC reward in squirrel monkeys
Since THC self-administration in squirrel monkeys provides the most congruent animal
model of human cannabinoid abuse31, we used this model to examine the effects of Ro
61-8048. We also tested the effects of Ro 61-8048 in monkeys trained to self-administer
food and cocaine under the same schedule of reinforcement (fixed ratio 10, FR10) to
determine whether the effects of Ro 61-8048 are specific to cannabinoid reward.
At the peak of the THC self-administration dose-effect curve (4 μ g per kg per injection
THC; Fig. 5a), squirrel monkeys self-administered an average of 50.80 ± 1.90 injections per
session and lever-pressed at an average rate of 1.20 ± 0.25 responses per second in the
presence of a green light signaling THC availability. Self-administration of this THC dose
was investigated in monkeys over three consecutive days of treatment with Ro 61-8048 (10
or 20 mg per kg, 40 min before each session). Ro 61-8048 significantly and dose-
dependently reduced THC self-administration during all three sessions (Fig. 5a; 10 mg per
kg Ro 61-8048: F3,12 = 4.07; P = 0.033; 20 mg per kg Ro 61-8048: F3,12 = 30.93; P <
0.001). Self-administration behavior returned to baseline levels when Ro 61-8048 treatment
ended.
In the food self-administration model (Fig. 5b), monkeys self-administered 53.46±1.29 food
pellets per session on average, with a response rate of 1.97 ± 0.66 responses per second in
the presence of a green light signaling food availability. During three daily sessions with Ro
61-8048 pretreatment, food-reinforced responding in monkeys was not affected by either 10
or 20 mg per kg of Ro 61-8048 under testing conditions that paralleled those used to
evaluate THC self-administration (Fig. 5b; 10 mg per kg Ro 61-8048: F3,9 = 1.76, P = 0.22;
20 mg per kg Ro 61-8048: F3,9 = 1.77, P = 0.22). Thus, Ro 61-8048 did not produce a non-
specific disruption of behavior.
Moreover, Ro 61-8048 (20 mg per kg i.m., 40 min before the session) reversed the
disruptive effects of THC (0.56 mg per kg i.v., immediately before the session) on food-
maintained self-administration behavior (Supplementary Fig. 1a; pellets per session: F3,6 =
23.29, P = 0.001, post-hoc analysis - P = 0.003; Supplementary Fig. 1b rate of responding:
F3,6 = 15.37, P = 0.003, post-hoc analysis, THC 0.56 vs. Ro 61-8048 20 + THC 0.56 - P =
0.018). Treatment with 0.56 mg per kg THC alone significantly reduced both the rate of
food-maintained responding (from 0.90 ± 0.17 to 0.09 ± 0.03 responses per second) and the
number of food pellets per session (from 49.5 ± 1.76 to 19.00 ± 4.51) compared to levels
observed after vehicle treatment (post-hoc analysis, vehicle vs. THC 0.56: rate of responding
- P = 0.003; pellets per session - P = 0.002). Pretreatment with Ro 61-8048 had no effect by
itself (post-hoc analysis, vehicle vs. Ro 61-8048 20: rate - P = 0.28, pellets - P = 0.93), but
completely reversed the effects of THC on rates of responding (to 0.62 ± 0.08 responses per
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tsecond; post-hoc analysis, vehicle vs. Ro 61-8048 20 + THC 0.56 - P = 0.22) and food
intake (to 46.67 ± 1.45 pellets per session; post-hoc analysis - P = 0.91).
In monkeys trained to self-administer cocaine (Fig. 5c), the dose of Ro 61-8048 (20 mg per
kg) that effectively decreased THC self-administration did not alter cocaine self-
administration (30 μ g per kg per injection). Monkeys averaged 44.56 ± 0.62 injections per
session with a mean response rate of 0.54 ± 0.04 responses per second in the presence of a
green light signaling cocaine availability. Pretreatment with Ro 61-8048 40 min before each
of three daily sessions did not significantly affect cocaine self-administration during those
sessions (Fig. 5c; F3,6 = 1.33; P = 0.35).
Rates of lever responding were significantly affected during Ro 61-8048 treatment only in
the group self-administering THC (Fig. 5d; 10 mg per kg Ro 61-8048: F3,12 = 9.82; P =
0.001; 20 mg per kg Ro 61-8048: F3,12 = 15.92; P < 0.001). In monkeys self-administering
food or cocaine, response rates were not affected by treatment with Ro 61-8048 (Fig. 5e;
food self-administration; 10 mg per kg Ro 61-8048: F3,9 = 1.1; P = 0.40; 20 mg per kg Ro
61-8048: F3,9 = 1.61, P = 0.26; Fig. 5f; cocaine self-administration: F3,6 = 0.69; P = 0.59).
To further characterize the nature of the effects of Ro 61-8048 on THC self-administration,
we varied the dose of THC and obtained classic inverted U-shaped dose-effect curves (Fig.
5g,h). THC maintained significantly more self-injections (Fig. 5g; F6,22 = 29.34, P < 0.001)
than vehicle at 0.5, 1, 2, 4 and 8 μ g per kg per injection, and significantly higher rates of
responding (Fig. 5h; F6,22 = 36.76, P < 0.001) than vehicle at 4 μ g per kg per injection. We
found that pretreatment with 20 mg per kg of Ro 61-8048 significantly shifted the THC
dose-response curve for injections per session down and to the right (Fig. 5g; interaction of
THC and Ro 61-8048; F5,17 = 35.45, P < 0.001), consistent with a decrease in THC’s
rewarding effects. This Ro 61-8048 dose also produced a significant downward-rightward
shift for response rates (Fig. 5h; interaction of THC and Ro 61-8048; F5,17 = 16.10, P <
0.001). Post-hoc pairwise comparisons revealed significant differences in the effects of 1, 2,
4, and 16 μ g THC per kg per injection after Ro 61-8048 pretreatment on the number of self-
administered injections per session (all P < 0.001), and significant differences in effects of 2,
4 and 16 μ g per kg THC per injection after Ro 61-8048 pretreatment on response rates (dose
2: P = 0.04; dose 4: P < 0.001; dose 16: P = 0.012). The total amount of THC received
during the session was significantly decreased by Ro 61-8048 across most of the dose-effect
function (Fig. 5i; F5,17 = 59.4, P < 0.001), but increased at the highest dose per injection.
We then asked whether positive allosteric modulators of α 7nAChRs (i.e., galantamine and
PNU120596) would prevent the effects of Ro 61-8048 on THC self-administration in
monkeys. Galantamine (0.3–3 mg per kg, i.m.) dose-dependently prevented the effects of Ro
61-8048 (20 mg per kg, i.m.) on THC self-administration in monkeys (Fig. 6a; F4,12 =
36.48, P < 0.0001), but galantamine alone (0.3–3 mg per kg, i.m) had no significant effect
(Fig. 6b; F3,9 = 3.41, P = 0.067). Like galantamine, PNU120596 also dose-dependently
(0.3–3 mg per kg, i.m.) prevented the effects of Ro 61-8048 (20 mg per kg, i.m.) on THC
self-administration in monkeys (Fig. 6c; F4,12 = 35.71, P < 0.0001) but had no significant
effect when given alone (0.3–3 mg per kg, i.m) (Fig. 6d: F3,9 = 1.98, P = 0.19). Thus, we
confirmed that α 7nAChRs are involved in the ability of Ro 61-8048 to block the reinforcing
effects of THC in nonhuman primates.
KMO inhibition and relapse in squirrel monkeys
To further study the effects of KMO inhibition in animal models of relapse to THC seeking,
we determined whether Ro 61-8048 blocked reinstatement induced by re-exposure to THC
or THC-associated cues, in squirrel monkeys, and whether α 7nAChRs were involved in this
blockade, When lever-press responding for THC had been extinguished by discontinuing
Justinova et al. Page 6
Nat Neurosci. Author manuscript; available in PMC 2014 May 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tTHC delivery, administration of a non-contingent priming injection of THC (0.04 mg per
kg, i.v.) before the session reinstated drug-seeking (Fig. 6e: F5,14 = 34.37, P < 0.001; Fig. 6f:
F5,13 = 77.81, P < 0.001). Treatment with Ro 61-8048 (20 mg per kg, i.m.) blocked this
THC-induced reinstatement (Fig. 6e,f: both P < 0.001 vs. THC), and pretreatment with
either galantamine (3 mg per kg) or PNU120596 (1 mg per kg) prevented this blockade (Fig.
6e,f). Ro 61-8048 alone did not reinstate drug-seeking behavior (Fig. 6e,f). Both
galantamine and PNU120596 produced a low level of reinstatement of drug-seeking
behavior (Fig 6e: P = 0.033vs. vehicles, Fig 6g: P = 0.012 vs. vehicles), but this effect was
significantly smaller than the reinstatement produced by a priming injection of THC (Fig.
6e: P < 0.001 vs. THC; Fig. 6f: P < 0.001 vs. THC).
Since relapse can be triggered by re-exposure to drug-related environmental cues, we looked
at cue-induced reinstatement of THC seeking. When both THC delivery and presentation of
cues signaling delivery of THC were discontinued, THC seeking by the monkeys decreased
to very low levels (Fig. 6g,h). When visual cue presentation was restored and i.v. vehicle
was delivered contingent on responding, THC-seeking behavior was reinstated (Fig. 6g:
F5,13 = 21.16, P < 0.001; Fig. 6h: F5,10 = 57.87, P < 0.001). This cue-induced reinstatement
was significantly decreased by Ro 61-8048 (20 mg per kg) (Fig. 6g, h). Pretreatment with
either galantamine (3 mg per kg) or PNU120596 (1 mg per kg) prevented these effects of Ro
61-8048 (Fig. 6g,h). When Ro 61-8048, galantamine or PNU120596 were given with THC’s
vehicle without presentation of cues, THC-seeking behavior was not reinstated (Fig. 6g;
post-hoc analysis vs. vehicle + no cues: Ro 61-8048 P = 0.95; galantamine P = 1.00; Fig 6h;
Ro 61-8048 P = 0.79; PNU120596 P = 0.69). These results suggest that treatment with a
KMO inhibitor could prevent relapse caused by re-exposure to THC or to THC-associated
cues, and that this effect of KMO inhibition occurs via an α 7nAChR-mediated mechanism.
Effects of KMO inhibition and THC on working memory
Since excessive levels of KYNA may be associated with cognitive impairment43,44, and
since THC is well known to impair memory, effects of Ro 61-8048 on working memory
were tested in rats trained with a delayed nonmatching-to-position procedure and in squirrel
monkeys trained with a delayed matching-to-sample procedure. In rats, THC (3 or 5.6 mg
per kg) and Ro 61-8048 (100 mg per kg) were administered alone and in combination. Ro
61-8048 had no effect on memory when given alone (Fig. 7a), but THC decreased accuracy
in a delay-dependent manner, consistent with a selective impairment of working memory
(Fig. 7b). Ro 61-8048 did not alter the effects of THC (Fig. 7c,d). The main effects of THC
(F2,13 = 13.56; P < 0.0001) and delay (F4,28 = 47.34; P < 0.0001) were both significant, but
the effects of Ro 61-8048 were not (P=0.85). Paired comparisons indicated that both doses
of THC significantly impaired working memory (P < 0.0035).
In squirrel monkeys, working memory was also impaired by THC alone (0.1 mg per kg) but
not by Ro 61-8048 (20 mg per kg) alone (Fig. 7e,f). Accuracy in monkeys was also
decreased slightly by THC at short delay values, suggesting that impairments might have
been due in part to nonselective disruption by THC, similar to the disruptions in food-
maintained behavior described above. THC-induced impairments in monkeys were reversed
by Ro 61-8048 (Fig. 7f: main effect of Ro 61-8048: F1,2 = 20.46; P < 0.05; main effect of
THC: F1,2 = 42.42; P < 0.05; main effect of delay: F4,8 = 59.65; P < 0.0001).
KMO inhibition and discriminative-stimulus effects of THC
To determine whether Ro 61-8048 can affect not only the reinforcing effects of THC, but
also its subjective effects, we studied effects of Ro 61-8048 in rodent and primate models of
cannabinoid discrimination. In rats trained to detect whether they had been injected with
THC or its vehicle, lever selection was dose-dependent, with maximal selection of the drug
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tlever (99.66%) at the 3 mg per kg training dose of THC (Fig. 8a; F5,40 = 28.03; P < 0.001).
Notably, the THC dose-effect curve was not significantly shifted by treatment with either 30
or 100 mg per kg of Ro 61-8048 (Fig. 8a; F2,45 = 2.66; P = 0.1), indicating that Ro 61-8048
does not block all of the subjective effects of cannabinoid CB1 agonists in rats. Also in this
procedure, Ro 61-8048 did not disrupt food-reinforced behavior when given alone (Fig. 8b;
F2,16 = 0.53; P = 0.59) or in combination with different doses of THC (Fig. 8b; F2,45 = 0.24;
P = 0.79), indicating that decreases in WIN 55,212-2 self-administration produced by Ro
61-8048 in rats (Fig. 4d,e) were not due to nonspecific behavioral disruption.
In squirrel monkeys trained to discriminate the cannabinoid CB1 agonist AM4054 (0.01 mg
per kg) from vehicle, THC generalized to the cannabinoid CB1 training stimulus in a dose-
dependent manner (Fig 8c; F3,6 = 864.0; P < 0.001). This dose-effect curve was significantly
shifted to the right by treatment with 20 mg per kg of Ro 61-8048 (Fig. 8c; F2,15 = 152.32; P
< 0.001), but not by 10 mg per kg of Ro 61-8048 (Fig. 8c). Ro 61-8048 did not affect rates
of responding in this task (Fig. 8b; F2,11 = 4.54; P = 0.09).
Discussion
The present results indicate that pharmacological modulation of brain KYNA levels by
KMO inhibitors could provide an effective approach for the treatment of marijuana
dependence. It is well-established that THC, like other drugs of abuse, elevates extracellular
levels of dopamine in the NAc shell2,7,11, an effect that is mediated by cannabinoid CB1
receptors and presumably underlies the rewarding and dependence-inducing effects of
marijuana. Systemic administration of the KMO inhibitor Ro 61-8048 in rats increased
extracellular KYNA levels in the VTA and NAc shell and substantially reduced the ability
of THC or the synthetic cannabinoid WIN 55,212-2 to stimulate dopamine release in these
areas. This blockade of THC’s effects appears to be due to actions of KYNA in the NAc
shell, since, like systemic administration, local infusion of KYNA into the shell also
prevented THC from elevating extracellular dopamine levels.
Ro 61-8048 also produced highly promising results in behavioral models of drug abuse. In
rats, it markedly reduced self-administration of the synthetic cannabinoid WIN 55,212-2. In
monkeys, Ro 61-8048 decreased the rewarding effects of THC, as demonstrated by a shift of
the self-administration dose-response curves of THC down and to the right. After
pretreatment with Ro 61-8048, THC intake was reduced over a wide range of THC doses
and increased only at the highest THC dose. This increase is consistent with a reduced
rewarding effect of high THC doses, and may also be due to the reversal by Ro 61-8048 of
rate-depressing effects of THC such as we observed in monkeys self-administering food.
Relapse to drug use (as opposed to initial achievement of abstinence) is typically the main
obstacle to successful cessation of drug use. In abstinent monkeys with extensive histories of
THC self-administration, Ro 61-8048 prevented relapse-like THC-seeking behavior induced
by re-exposure to THC. Parallel effects were obtained in rats, where Ro 61-8048 prevented
drug-induced seeking of WIN 55,212-2. Moreover, Ro 61-8048 was able to block the
relapse-inducing effects of THC-associated cues in monkeys, suggesting it might reduce
drug craving in humans.
The ability of the KMO inhibitor Ro 61-8048 to reduce neurochemical and behavioral
effects of THC in rats and monkeys was prevented by galantamine, an agonist at the
allosteric potentiating site of α 7nAChRs that overlaps with the site where KYNA acts as an
antagonist24. Since galantamine is also a weak cholinesterase inhibitor, we confirmed
prevention of the effects of Ro 61-8048 using PNU120596, a selective positive allosteric
modulator of α 7nAChRs that does not inhibit cholinesterase42. These results indicate that
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tthe anti-abuse actions of KMO inhibition are due to KYNA-induced negative allosteric
modulation of α 7nAChRs.
Although further experimentation will be required to fully elucidate the circuitry and
mechanisms involved in KYNA’s ability to block cannabinoid reward, the available
evidence supports the following hypothesis. THC and WIN 55,212-2 facilitate dopamine
release in the NAc shell5,6,45, and this is believed to be due at least in part to activation of
excitatory glutamatergic pyramidal neurons that project from the prefrontal cortex to the
VTA and NAc shell46,47. Since α 7nAChRs are localized on the terminals of these
glutamatergic cells8, negative allosteric modulation of α 7nAChRs by KYNA could reduce
the release of glutamate by these cells and thereby reduce glutamate-induced dopamine
release in the VTA and NAc shell9,10,45. Since elevated levels of dopamine in the NAc shell
are considered central to the rewarding effects of cannabinoid drugs2, and as local infusion
of KYNA directly into the NAc shell was sufficient to completely block THC-induced
dopamine elevations, it is likely that effects of KYNA in the shell of the NAc are a main
factor underlying the ability of Ro 61-8048 to reduce the rewarding effects of cannabinoids.
The safety of KMO inhibitors in humans will have to be considered in future translational
studies. Although high levels of KYNA have been associated with cognitive deficits43,44, Ro
61-8048 has neuroprotective and anticonvulsant effects in animal models30. In our
experiments, we found that the effects of Ro 61-8048 were specific to cannabinoid reward
and were not associated with adverse side effects. Of special relevance, the modest increase
in brain KYNA produced by Ro 61-8048 did not adversely affect working memory in rats or
squirrel monkeys in tests highly sensitive to impairments induced by THC and other
amnesic agents48. Moreover, in rats, KMO inhibition by itself neither produced THC-like
subjective effects nor altered the effects of THC itself, which are most likely comprised of
both reward-related and non-reward components. However, in squirrel monkeys, KMO
inhibition attenuated the discriminative-stimulus effects of THC. The reason(s) for this
species-specific effect may be related to differences in cannabinoid mechanisms between
rodents and primates31. Notably, moderate KMO inhibition did not affect baseline levels of
dopamine in the NAc shell or VTA in the present study, and is known not to affect brain
levels of the neurotoxic kynurenine pathway metabolites 3-hydroxykynurenine and
quinolinic acid36.
The decreases in cannabinoid self-administration observed here were not due to nonspecific
suppression of operant behavior. Although responses on an inactive lever were decreased
along with those on the active lever in the WIN 55,212-2 self-administration experiment
when rats received 100 mg per kg Ro 61-8048, the 30 mg per kg dose decreased WIN
55,212-2 self-administration without affecting inactive-lever responses. Moreover, the
higher dose of Ro 61-8048 did not alter food-maintained behavior in rats. In monkeys, Ro
61-8048 did not affect food or cocaine self-administration behavior, and, in fact, reversed
rate-depressant effects of THC on food self-administration.
Taken together, our results suggest that KMO inhibitors could be safe and effective,
decreasing cannabinoid reward and relapse at doses devoid of adverse behavioral or
neurotoxic effects. Since enhancing endogenous KYNA levels counteracts the abuse-related
effects of THC through negative allosteric modulation of α 7nAChRs, rather than by direct
interference with CB1 receptor function, drugs such as Ro 61-8048 might be better tolerated
than orthosteric inverse agonists or antagonists of CB1 receptors, which can have adverse
side effects due to actions at CB1 receptors not directly related to THC abuse49.
A medication that would safely and effectively assist in the treatment of marijuana
dependence would be an important step forward in dealing with cannabis-use disorders. In
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tthe present study, KMO inhibition selectively blocked cannabinoid reward and also had the
highly-promising effect of counteracting the ability of drugs and drug-related cues to trigger
relapse to cannabinoid seeking. As in rodent or non-human primate models of neurological
diseases, where KMO inhibition provides marked benefits ranging from behavioral
remediation to neuroprotection35,36,50, pharmacological elevation of brain KYNA offers an
attractive novel strategy for treating human marijuana dependence.
Online methods
Animals
Male squirrel monkeys (Saimiri sciureus) weighing 0.8-1.1 kg, male Sprague-Dawley rats
(Charles River Laboratories, Wilmington, MA) and male Long-Evans rats (Charles River
Laboratories, Wilmington, MA) weighing 300-350 g were singly housed and maintained in
temperature- and humidity-controlled facilities fully accredited by AAALAC. Animals were
housed on a regular 12 h:12 h light/dark cycle (lights on from 7:00 am), in temperature- and
humidity-controlled facilities. Experiments were conducted in light phase. Only for the WIN
55,212-2 experiments, male Lister Hooded rats (Harlan–Nossan, Italy) weighing 250–275 g
were housed 4 per cage on a reversed 12 h:12 h light/dark cycle (lights on from 7:00 pm).
Rats started the experiments at age 8 weeks. Ages of monkeys ranged from 8 – 15 years.
Monkeys had a previous self-administration history.
Experiments were approved by the Animal Care Committees of NIDA IRP, Harvard
Medical School/Mclean Hospital and the University of Cagliari and were carried out in strict
accordance with the 2003 National Research Council guidelines or the E.C. Regulations for
Animal Use in Research (CEE No. 86/609).
Drugs
Δ 9-tetrahydrocannabinol (THC; NIDA Research Resources Drug Supply Program,
Bethesda, MD, USA) was dissolved in a vehicle containing 1% ethanol and 1% Tween 80 in
saline for monkeys and 40% cyclodextrin in saline for rats. (R)-(+)-WIN 55,212-2 mesylate
salt (WIN 55,212-2, Sigma-Aldrich, Italy) was dissolved in one drop of Tween 80, and
diluted in heparinized (1%) sterile saline solution (volume of injection: 0.1 mL). 3,4-
dimethoxy-[-N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048, Sai
Advantium Pharma, Hyderabad, India) was dissolved in a vehicle containing 5-6% Tween
80 in saline and injected typically 40 min before the session (b.s.; behavioral experiments)
or before THC or WIN 55,212-2 (microdialysis experiments) unless noted otherwise.
Galantamine (Sigma-Aldrich, St. Louis, MO) was dissolved in saline. PNU120596 (Sigma-
Aldrich, St. Louis, MO) was dissolved in a vehicle containing 5% ethanol and 5%
cremophor EL in saline. Both galantamine and PNU120596 were always injected 50 min
b.s. in behavioral experiments or 60 min before THC or vehicles in microdialysis
experiments.
In-vivo microdialysis in freely-moving rats
Experiments with THC—The general procedure was described previously11,26. Dialysis
(perfusion rate: 1 μ l per min) was performed in Sprague-Dawley rats 20-24 h after
implantation of probes aimed at the NAc shell (2.0 mm anterior and 1.1 mm lateral from
bregma, 8.0 mm below the dura) or the VTA (5.3 mm posterior to, and 0.9 mm lateral from,
bregma, 8.4 mm below the dura)51. Samples (20 μ l) were collected every 20 min. Dopamine
levels were immediately analyzed by HPLC coupled to electrochemical detection while
samples for KYNA determination were frozen and analyzed later. Test drugs or vehicles
were injected after stable dopamine levels (≤15% variation) were obtained in three
consecutive samples. Ro 61-8048 (30 or 100 mg per kg i.p.) was injected 40 min before
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tTHC (3 mg per kg i.p.) injection. Galantamine (3 mg/kg) or PNU120596 (1 mg/kg) were
injected i.p. 60 min before THC or vehicles. KYNA was dissolved in Ringer solution and
delivered by reverse dialysis at a constant flow rate of 1 ul per l through a concentric probe
implanted in the NAc shell and following the coordinates previously described. Ringer
+vehicle or Ringer+KYNA were infused after stable dopamine levels (≤15% variation)
obtained in three consecutive samples. Perfusion with KYNA or vehicle continued until the
end of the experiment. THC (3 mg per kg, i.p.) was injected 40 minutes after KYNA
infusion started (500 nM), and dopamine samples were collected every 20 min for 3 h.
Experiments with WIN 55,212-2—Apparatus and procedure were the same as described
previously52. Male Lister Hooded rats were surgically implanted with a dialysis probe aimed
at the shell of the nucleus accumbens (1.6 mm anterior and 1.1 mm lateral from bregma, 7.9
mm below dura)51, and dialysate samples were collected every 20 min and immediately
analyzed by an HPLC system coupled to electrochemical detection. Ro 61-8048 (30 and 100
mg per kg i.p.) or its vehicle were injected 40 min before WIN 55,212-2 (0.3 mg per kg i.v.;
average basal levels of dopamine: 67.26 ± 10.80 fmol per 10 μ l) or vehicle. Only rats with
correct probe placement were included in the study.
Intravenous self-administration of WIN 55,212-2 by rats
The general procedure was the same as described previously53. Briefly, under deep
anesthesia, rats were surgically implanted with a catheter in the right jugular vein and left to
recover for 6–7 d before starting self administration training. In this study, animals were
trained to press a lever for a response-contingent injection of WIN 55,212-2 (12.5 μ g per kg
per injection) under a continuous fixed-ratio one (FR1) schedule of reinforcement during 2-h
daily sessions. There was a 10-s timeout period after each injection. After stabilization of
daily intake (no more than 15% variation over 3 sessions), Ro 61-8048 pretreatment
(vehicle, 30 and 100 mg per kg i.p.) was tested for three sessions.
WIN 55,212-2-induced reinstatement of extinguished drug-seeking behavior in rats
Self-administration of WIN 55,212-2 was extinguished by replacing WIN 55,212-2 with
vehicle (1% Tween 80 in saline), leaving all other experimental parameters unchanged.
Once extinction criteria were reached (mean number of active-lever presses decreased by
85% or more for at least five sessions), rats were randomly divided into groups and were
given a priming injection of either saline, WIN 55,212-2 (0.3 mg per kg i.p., 10 min b.s.), or
0.3 mg per kg WIN 55,212-2 plus 100 mg per kg Ro 61-8048 in a counterbalanced within-
subject design. Lever pressing was then monitored during a 2-h reinstatement test session in
which responding resulted in intravenous injections of saline, as before.
Intravenous self administration of THC by monkeys
Monkeys self-administered THC (4 μ g per kg per injection; FR10; 60-s timeout; paired
visual stimulus; 1-h sessions)31,54. When responses showed <15% variability for at least 5
consecutive sessions, Ro 61-8048 pretreatment (vehicle, 10 and 20 mg per kg, i.m.) was
tested for three sessions. Ro 61-8048 (10 and 20 mg per kg) was also examined under
parallel conditions in separate groups of monkeys self-administering 190-mg food pellets or
intravenous cocaine (30 μ g per kg per injection). Effects of Ro 61-8048 (20 mg per kg) on
the THC dose-response curve (0.5, 1, 2, 4, 8, and 16 μ g per kg per injection) were also
assessed, with each dose combination tested for three consecutive sessions, preceded and
followed by 3-4 sessions with vehicle pretreatment. Single-session pre-treatment with
galantamine or PNU120596 (both 0.3, 1, 3 mg per kg i.m.) was tested to determine whether
it altered the effects of Ro 61-8048 (20 mg per kg) or vehicle on THC self-administration (4
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tμ g per kg per injection). Galantamine and PNU120596 doses were tested in ascending order
in two monkeys and in descending order in the other two.
In a group of monkeys self-administering food, we also tested effects of different doses of
THC (0.04–0.56 mg per kg i.v., immediately b.s.) to find a dose that disrupts food self-
administration. We then administered this dose (0.56 mg per kg) after pretreatment with Ro
61-8048 (20 mg per kg i.m.) to assess whether the disruption of the food-maintained
behavior can be reversed by KMO inhibition.
THC-induced reinstatement of extinguished drug-seeking behavior in monkeys
Monkeys that self-administered THC (4 μ g per kg per injection) were placed under
extinction by substituting vehicle for THC. When responses reached a low, stable level,
priming injections of THC (vehicle or 0.04 mg per kg i.v., immediately b.s.) were tested
with vehicles or 20 mg per kg Ro 61-8048 pretreatment (i.m.). Galantamine (3 mg per kg
i.m.) or PNU120596 (1 mg per kg i.m.) were given alone or in combination with THC
priming and 20 mg per kg Ro 61-8048 pretreatment. Ro 61-8048 pretreatment was also
tested with combination of vehicles. Each test was preceded and followed by one or two
extinction sessions. Pretreatment with combination of vehicles was given prior to extinction
sessions.
Cue-induced reinstatement of THC seeking in monkeys
After the completion of THC-induced reinstatement testing, monkeys were returned to
baseline THC self-administration for several weeks. Then, presentation of THC-associated
visual cues and intravenous injections were discontinued for 3 extinction sessions. Cue-
induced reinstatement tests (with 1-2 extinction sessions before each test) were then
conducted by reinstituting response-contingent cue presentations and delivering saline
injections on the FR10 schedule, after pretreatment with vehicles or Ro 61-8048 (20 mg per
kg i.m.) combined with vehicle, galantamine (3 mg per kg i.m.) or PNU120596 (1 mg per kg
i.m.). Pretreatments with combination of vehicles, vehicles plus Ro 61-8048 (20 mg per kg),
vehicles plus galantamine or vehicles plus PNU120596 were also given prior to selected
extinction sessions.
Delayed nonmatching-to-position procedure in rats
The procedure was described previously55. Briefly, male Long-Evans rats were trained in a
chamber with a horizontal array of three apertures. During each trial, the house light was
extinguished, and one of the two side apertures (left or right) was lit from within as a
sample. After two responses in the sample aperture, the aperture light was extinguished, and
the delay period began (0, 7, 14, 21, or 28 s, in pseudo-random order over trials). The first
response in the center aperture after the designated delay lit both side apertures. If the rat
responded correctly (i.e., in the nonmatching aperture, opposite to the sample), it received a
45-mg food pellet. The next trial began after a 15-s timeout period with the house light on.
Sessions lasted until 100 pellets were delivered or after 90 min. THC (3 or 5.6 mg per kg)
was given i.p. 40 min b.s., and Ro 61-8048 (100 mg per kg) was given i.p. 100 min b.s.
Delayed matching-to-sample procedure in squirrel monkeys
The procedure was described in detail previously56. Briefly, male squirrel monkeys were
trained in a customized touch-screen chamber57. Trials began with presentation of a 7×7cm
digital photograph (sample stimulus). After twenty touch responses to the sample, the
stimulus was terminated and the delay period began (0, 2, 4, 8, or 16 s, in pseudorandom
order over trials). Following the delay, 2 comparison stimuli were presented left and right of
the midline. A touch response to the stimulus that matched the previously presented sample
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tresulted in delivery of 0.15 ml of the sweetened condensed milk reinforcer followed by a 10-
s timeout period, whereas a mismatch immediately initiated the timeout. Daily sessions were
comprised of 60 trials (12 trials of each delay). THC (0.1 mg per kg) was given i.m. 30 min
b.s., and Ro 61-8048 (20 mg per kg) was given i.m. 70 min b.s.
THC discrimination in rats
Rats were trained under a discrete-trials schedule of food reinforcement (10 responses per
pellet – FR10, 45-s timeout) in which responses on one lever produced food when an
injection of THC (3 mg per kg, i.p., 30 min b.s.) was given, and responses on the other lever
produced food when a vehicle injection was given58. Sessions lasted for 20 pellets or 30
min. Ro 61-8048 (vehicle, 30 or 100 mg per kg i.p., 70 min b.s.) and THC (vehicle, 0.3,
0.56, 1, 1.8 or 3 mg per kg i.p., 30 min b.s.) were given before test sessions, up to two times
per week. During test sessions, food was delivered whenever there were 10 consecutive
responses on either lever.
THC discrimination in squirrel monkeys
Squirrel monkeys responded under a 10-response fixed ratio (FR10) schedule of stimulus-
shock termination to identify injection of the cannabinoid CB1 agonist AM4054 (0.01 mg
per kg i.m., 50 min b.s.) from vehicle in a two-lever drug discrimination procedure59. The
two levers were designated as the drug (AM4054) and saline levers, with assignment
remaining the same for a subject throughout the study. Brief, low-intensity shock was
scheduled for delivery every 10 s until either the FR 10 was completed on the correct lever
or 30 s elapsed, whichever came first. Training sessions ended upon completion of 20 trials.
The test session consisted of four components of 10 trials, each component beginning with a
10-min timeout period. No shock deliveries were scheduled during test sessions. Cumulative
dosing procedures were used to establish dose-response relationships for the discriminative-
stimulus effects of THC (0.01-0.3 mg per kg i.m., 30 min b.s.) administered i.m. at the onset
of sequential 10-min timeout periods. Modification of the discriminative stimulus effects of
THC by Ro 61-8048 (vehicle, 10 or 20 mg per kg i.m., 70 min b.s.) was studied by
determining how pretreatment with Ro 61-8048 altered the position and per or slope of the
THC dose-effect function.
Statistical analysis
All data are presented as means ± s.e.m. The sample sizes were chosen based on our
previous experience with the used procedures and they are adequate to detect meaningful
differences between conditions. All data met the assumptions of the test with regard to the
normality, skew and homogeneity of variance. All tests were two-tailed. Rats were randomly
assigned to the groups for between-groups experiments in microdialysis experiments.
Counterbalanced assignment of treatment order for within-subject design was used in
behavioral experiments. Experimenters were not blind to the treatment assignment.
Microdialysis data were expressed as a percentage of basal KYNA and dopamine values;
basal values were the mean of three consecutive samples (differing from each other by
≤15%) taken immediately before the first injection of test compound or vehicle.
Microdialysis and behavioral data were analyzed using one-way or two-way repeated
measures (RM) analysis of variance (ANOVA) and Tukey paired comparisons. To compare
the effects of treatments in dialysis experiments, area under the curve (AUC) was calculated
and expressed for each condition as a percentage of the AUC for the group receiving THC
alone or WIN alone; simultaneous confidence intervals were used to determine whether the
condition differed from 0% (thereby indicating a significant change from baseline) or 100%
(thereby indicating a significant change vs. the THC-alone or WIN-alone group). Response
rates in self-administration experiments did not include responses or time elapsed during
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ttimeout. Self-administration responding after Ro 61-8048 treatment was compared to the
previous 1-3 consecutive sessions of vehicle treatment; for dose-effect curves, the last three
sessions under each condition were averaged. Reinstatement data (extinction baseline and
reinstatement test) represent the mean of 1-3 sessions under each condition. Working
memory data (arcsine-transformed percentage of trials with a correct response) were
analyzed with delay, THC dose, and Ro 61-8048 dose as factors.
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Effects of treatment with Ro 61-8048 on the extracellular concentration of kynurenic acid
(KYNA) in NAc shell and VTA of freely-moving rats. (a,b) Ro 61-8048 (30 and 100 mg per
kg i.p.) significantly increased extracellular KYNA levels in the NAc shell (a; basal levels:
2.29 ± 0.18 and 1.51 ± 0.1 nM, respectively) and VTA (b; basal levels: 1.61 ± 0.1 and 1.29
± 0.1 nM, respectively). KYNA reached peak concentrations 80 min after the injection of
100 mg per kg Ro 61-8048 in both brain areas. Arrows indicate time of Ro 61-8048
injection. Results are expressed as mean (± s.e.m) percentage of basal values (n = 6 per
group). *P < 0.05, **P < 0.01, ***P < 0.001, post-hoc vs. basal values.
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Effects of elevated brain levels of KYNA on THC-induced elevations of extracellular
dopamine levels in NAc shell and VTA of freely-moving rats. (a,b,c,d) THC (3 mg per kg)
increased dopamine levels compared to basal levels in both NAc shell (a; average basal
levels: 37.60 ± 2.70 fmol per 10 μ l; n = 7) and VTA (c; average basal levels: 26.18 ± 3.80
fmol per 10 μ l; n = 7). The effects of THC on dopamine in NAc shell (a,b) were
significantly attenuated by pretreatment with 100 mg per kg Ro 61-8048 (Ro; n = 6), and the
effects of THC on dopamine in VTA (c,d) were significantly attenuated by pretreatment
with 30 (n = 5) or 100 mg per kg Ro 61-8048 (n = 6). Ro 61-8048 alone (both n=5) did not
affect extracellular levels of dopamine in either area. (e,f) Local infusion of KYNA (500
nM) (n = 5) into NAc shell significantly reduced THC-induced dopamine elevations in NAc
shell (e,f; n = 5). Arrows indicate time of THC, Ro 61-8048 or vehicle injection or local
infusion of KYNA. Data are presented over the course of the session as a percentage of
basal levels (a,c,e), and during the first 120 min after THC or vehicle injection as area under
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tthe curve (AUC), expressed as a percentage of the mean level in the Vehicle + THC group
(b,d,f). Results are expressed as means ± s.e.m. * P < 0.05 vs. baseline, #P < 0.05 vs.
vehicle + THC.
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Prevention of the neurochemical effects of Ro 61-8048 by two agonists at the allosteric
potentiating site of the α 7nAChR, galantamine and PNU120596. (a,b) THC (3 mg per kg
i.p.; a: n = 7, b: n = 4) administration elevated extracellular dopamine in NAc shell (average
basal levels: 39.69 ± 5.05 fmol per 10μ l) of freely-moving rats. These THC-induced
increases in dopamine levels were blocked by Ro 61-8048 (100 mg per kg i.p., 40 min
before THC; a: n = 6; b: n = 5), and this blockade was prevented by pretreatment with
galantamine (a; 3 mg per kg i.p., 60 min before THC; n = 5) or PNU120596 (b; 1 mg/kg
i.p., 60 min before THC; n = 4). Galantamine (n = 5), PNU120596 (n = 4) or Ro 61-8048 (n
= 5) alone did not increase dopamine levels, and neither galantamine nor PNU120596 (both
n = 5) affected THC-induced dopamine increases. Dopamine levels are expressed as area
under the curve (“AUC”, relative to the mean level in the vehicle + vehicle + THC 3
condition) over the 180 min following THC or vehicle injection. Bars represent means ±
s.e.m. *P < 0.05, **P < 0.01, post-hoc vs. vehicles + THC 3; Dunnet’s test. “0 mg per kg”
represents vehicle.
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Effects of treatment with Ro 61-8048 on abuse-related effects of the synthetic CB1 agonist
WIN 55,212-2 in rats. (a,b) Ro 61-8048 (Ro; 30 or 100 mg per kg) reduced the increases in
extracellular dopamine levels produced by WIN 55,212-2 (WIN; 0.3 mg per kg) in NAc
shell (a). Ro 61-8048 alone did not significantly affect dopamine levels in NAc shell (b).
Results expressed as a percentage of basal values over time (all groups n = 4). Arrows
indicate time of injection. (c) Dopamine levels expressed as area under the curve (“AUC”,
relative to mean level in vehicle + WIN condition) over the 120 min following WIN or
vehicle injection. *P < 0.05 vs. baseline, #P < 0.05 vs. Veh + WIN. (d,e) Ro 61-8048
(sessions T1-T3), but not its vehicle (sessions B1-B3; recovery sessions R1-R2), dose-
dependently decreased the number of WIN injections (12.5 μ g per kg; 1 injection per active-
lever response) self-administered over 2-h sessions. Presses on active and inactive levers per
session are shown (n = 5). *P < 0.05,**P < 0.01, post-hoc vs. average of sessions B1-B3,
Tukey test. (f) Ro 61-8048 (100 mg per kg) blocked reinstatement of extinguished drug-
seeking induced by injection of WIN (0.3 mg per kg) (n = 5). Presses on active and inactive
levers per session are shown. **P < 0.01, post-hoc vs. vehicles; ## P < 0.01, post-hoc vs.
vehicle + WIN 0.3 condition, Tukey test. All points or bars represent the means ± s.e.m. The
symbol “0” represents vehicle.
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Effects of Ro 61-8048 on THC, food, and cocaine self-administration in squirrel monkeys.
(a-f) Ro 61-8048 (10 and 20 mg per kg i.m.) significantly decreased the number of THC
injections self-administered during one-h sessions (a) and decreased overall response rates
(d) by squirrel monkeys under a fixed-ratio ten (FR10) schedule at a THC dose of 4 μ g per
kg per injection (n = 5, means ± s.e.m). Ro 61-8048 did not significantly affect food-
reinforced behavior (b, e) or cocaine (30 μ g per kg per injection) self-administration
behavior (c, f) in monkeys under conditions that paralleled the THC self-administration
procedure (n = 4 for food, n = 3 for cocaine, means ± s.e.m). Ro 61-8048’s vehicle was
given 40 min before each baseline session. (g-i) Pretreatment with Ro 61-8048 (20 mg per
kg) caused a significant (P < 0.001) rightward shift of the THC dose-response curves
compared to vehicle pretreatment. Number of THC injections per session (g), overall
response rates in the presence of the green light signaling THC availability (h) and total
THC intake per session (i) are shown as a function of the THC dose. For the dose-response
curves (g-i), each data point represents the mean ± s.e.m of the last three sessions under each
THC condition and under vehicle conditions (n = 3-5). *P < 0.05, **P < 0.01, post-hoc vs.
vs. the last session with vehicle pretreatment (session 3) (a-f) or vehicle conditions (g,h),
Bonferroni test. The symbol “V” represents vehicle.
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tFigure 6.
Reversal of behavioral effects of Ro 61-8048 by positive allosteric modulators of
α 7nAChRs. Galantamine (a) or PNU120596 (c) dose-dependently reversed the blockade of
THC (4 μ g per kg per injection) self-administration caused by pretreatment with Ro 61-8048
(20 mg per kg). Galantamine (b) and PNU120596 (d) alone had no significant effect. **P <
0.01, post-hoc vs. vehicles + THC 4; ##P < 0.01, post-hoc vs. vehicle + Ro 20 + THC 4,
Tukey test. (e,f) Treatment with Ro 61-8048 blocked the reinstatement of extinguished
THC-seeking responses produced by a priming injection of THC (0.04 mg per kg i.v.), and
this effect was prevented by pretreatment with galantamine (e) or PNU120596 (f). **P <
0.01, post-hoc vs. vehicles; ##P < 0.01, post-hoc vs. vehicles + THC 0.04, $$P < 0.01, post-
hoc vs. vehicle + Ro 20 + THC 0.04, Tukey test. (g,h) Treatment with Ro 61-8048 also
blocked the reinstatement of extinguished THC-seeking responses induced by reintroduction
of cues previously associated with THC, and this effect of Ro 61-8048 was reversed by
pretreatment with galantamine (g) or PNU120596 (h). *P < 0.05, **P < 0.01, post-hoc vs.
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tvehicles + no cues; ##P < 0.01, post-hoc vs. vehicles + cues, $$P < 0.01, post-hoc vs.
vehicle + Ro 20 + cues, Tukey test. N=4 for all conditions, except n=3 in panel h. Bars
represent means ± s.e.m. “0” represents vehicle in all panels. All doses expressed in mg per
kg, except THC in panels a-d (μ g per kg per injection).
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Effects of Ro 61-8048 and THC on working memory in rats and squirrel monkeys. (a-d)
The 100 mg per kg dose of Ro 61-8048, which was effective in blocking the effects of THC
in reward-related brain areas in rats, did not have deleterious effects on short-term memory
in rats when given alone (a) or in combination with THC (3 or 5.6 mg per kg i.p.) (c,d) in a
delayed nonmatching-to-position model of working memory. Both doses of THC
significantly decreased accuracy (b; P’s < 0.007), but this was not exacerbated by Ro
61-8048 (c,d). (e,f) The 20 mg per kg dose of Ro 61-8048, which was effective in blocking
the effects of THC in reward-related brain areas in monkeys, did not have deleterious effects
on short-term memory in monkeys when given alone (e) or in combination with THC (f) in a
delayed matching-to-sample model of working memory. THC (0.1 mg per kg i.m.)
significantly decreased accuracy (f), and this was reversed by Ro 61-8048 (f). Accuracy
(percentage of trials with a correct response) is shown (means ± s.e.m.; rats - n = 8; monkeys
- n = 3) as a function of delay and of drug treatment.
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Effects of Ro 61-8048 on discriminative-stimulus effects of THC in rats and squirrel
monkeys. (a,b) Rats trained to discriminate THC (3 mg per kg, i.p.) from vehicle (V) under
a fixed-ratio (FR10) schedule of food delivery were tested with various doses of THC, and
the percentage of responses on the CB1-appropriate lever was a monotonically increasing
function of dose. Treatment with Ro 61-8048 (30 or 100 mg per kg i.p.) did not significantly
alter this curve (a) and Ro 61-8048 did not significantly alter the rate of food-reinforced
responding after THC or vehicle administration (b). Abscissae, dose, log scale; ordinate,
percent of responses on the THC-associated lever (a), or response rate (b). (c,d) When
monkeys, trained under a stimulus-shock termination schedule to discriminate injection of
the selective cannabinoid CB1 agonist AM4054 (0.1 mg per kg i.m.) from vehicle, were
injected i.m. with various doses of THC, the percentage of responses on the CB1-appropriate
lever was a monotonically increasing function of cumulative dose (c). Ro 61-8048 (20 mg
per kg i.m.) reduced the monkey’s ability to detect interoceptive effects of THC in the
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tcannabinoid CB1 discrimination procedure (c). Ro 61-8048 did not significantly affect
response rates after THC administration in this procedure (d). Abscissae, cumulative THC
dose, log scale; ordinate, percent of responses on the AM4054-associated lever (c), or
response rate (d). Symbols left of the abscissae break indicate performance during vehicle
and AM4054 control sessions. All data are presented as means ± s.e.m (rats n=9, monkeys
n=3).
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